After more than 70 years of development, hematopoietic stem cell transplantation (HSCT) has become an important method to cure malignant hematological tumors in hematology department. However, postoperative hemorrhagic cystitis (HC) mainly caused by radiotherapy and chemotherapy drugs, viral infection and graft-versus-host disease (GVHD) has a high mortality rate, which is an important factor affecting the transplantation efficacy of patients. In addition to traditional treatments, some new treatment options have been discovered in recent years. At present, the main treatment options for this disease include preventive treatment, antiviral treatment, surgical treatment, traditional Chinese medicine treatment, and GVHD treatment. This article reviews the latest progress in the treatment of HC after HSCT at home and abroad in recent years, and discusses the advantages and disadvantages of different treatment methods.

Hematological malignancies are a serious disease with a high risk of mortality and a high tendency to recur. The current mainstream treatment methods mainly include chemotherapy, targeted therapy, supportive therapy, and hematopoietic stem cell transplantation. Immune cell therapy can induce the function of immune cells and accurately kill tumors and pathogens. For those refractory patients who experience relapse or have poor response to traditional treatments, the immune cell therapy has good clinical efficacy. This article reviews the latest advances in immune cell therapy for hematological malignancies.

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective treatment strategy for hematologic malignancies such as leukemia. Allo-HSCT rebuilds the hematologic and immune systems and exerts graft-versus-leukemia (GVL) effect, but at the same time it poses a risk of causing acute graft-versus-host disease (aGVHD). However, the challenge of preserving the GVL effect while preventing aGVHD remains unsolved. In current clinical treatment, immunosuppressants are mainly used to treat severe aGVHD, but the treatment effect is not satisfactory, and immunosuppressants can weaken or eliminate the GVL effect. aGVHD is mainly due to host response to graft and host challenge by donor T cells and cytokines in the early post-allo-HSCT period. T cell-mediated alloreactivity is the key to the GVL effect. In patients who have undergone allo-HSCT, the GVL effect should be more effective in the presence of aGVHD. This article reviews the impact and application of immune cells such as T cells on the preservation of GVL effect after allo-HSCT, aiming to provide new ideas and directions for the preservation of GVL effect.

Acute leukemia is a common hematological malignancy.Conventional chemotherapy,targe-ted drug therapy,hematopoietic stem cell transplantation and other treatment methods have made progress,but the mortality rate of patients after recurrence is still high.Adoptive cell therapy(ACT)has emerged as an effective therapeutic option for acute leukemia,particularly chimeric antigen receptor(CAR)T-cell therapy,which has demonstrated remarkable efficacy in treating B-cell acute lymphoblastic leukemia(B-ALL)and ma-lignant lymphoma.However,CAR-T cell therapy may induce cytokine release syndrome.Recent studies have highlighted the potent anti-leukemia effects of CAR-NK cell therapy.This review summarizeed the research progress of ACT employing various immune cells targeting different antigens in the treatment of acute leukemia.

Objective:To investigate the significance of Th1/Th2 cytokines in prognostic stratification of acute myeloid leukemia (AML).Methods:A total of 83 patients with newly diagnosed AML from June 2017 to April 2019 in the First People's Hospital of Yunnan Province were collected. According to the Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (non-acute promyelocytic leukemia) (2017 edition), AML patients were divided into poor prognosis group (45 cases), moderate prognosis group (19 cases), and good prognosis group (19 cases); moderate prognosis plus poor prognosis was treated as the not good prognosis. Mann-Whitney U test and Kruskal-Wallis H test were used to compare the expression differences of Th1/Th2 cytokines in peripheral blood of different prognosis groups; cytokines with statistical differences among different prognosis groups were selected, and the cut-off value of AML patients with different prognostic stratification distinguished by cytokines was determined by using receiver operating characteristic (ROC) curve. Finally, patients were divided into ≥ cut-off value group and 0.05).The cut-off value of TNF-β was 3.23 pg/ml in good prognosis group and moderate prognosis group, the area under the ROC curve was 0.866 (95% CI 0.753-0.978, P < 0.05); among 26 patients with TNF-β≥ 3.23 pg/ml, 25 (96.2%) patients had not good prognosis. The cut-off value was 3.62 pg/ml for distinguishing between moderate prognosis group and poor prognosis group, the area under the ROC curve was 0.747 (95% CI 0.610-0.884, P = 0.02); 18 (100%) patients with TNF-β≥ 3.62 pg/ml had not good prognosis. The cut-off value was 2.19 pg/ml for distinguishing between good prognosis group and not good prognosis group, the area under the ROC curve was 0.719 (95% CI 0.595-0.842, P = 0.04); among 53 patients with TNF-β≥2.19 pg/ml, 46 (86.8%) patients had not good prognosis. Conclusions:The high expression of TNF-β may indicate that the prognosis of AML patients is not good. When the level of TNF-β was equal or greater than 3.62 pg/ml, it may contribute to the prognostic stratification of AML patients.

Objective:To observe the therapeutic efficacy and prognosis of daratumumab combined with chemotherapy bridging to allogeneic hematopoietic stem cell transplantation (allo-HSCT) followed by daratumumab and lenalidomide maintenance treatment for primary plasma cell leukemia (PCL).Methods:The clinical data of a patient with primary PCL admitted to the First People's Hospital of Yunnan Province in January 2020 were retrospectively analyzed, and relevant literatures were reviewed.Results:The patient was diagnosed with primary PCL and treated with daratumumab combined with BD (bortezomib + dexamethasone) for 1 course and BCDD (bortezomib + cyclophosphamide + liposomaldoxorubicin + dexamethasone) for two courses. The patient was treated with daratumumab combined with allo-HSCT after complete remission. The donor cells were successfully implanted and the chimerism rate of donor cells was 94.36% without acute graft-versus-host disease reaction. And then the patient received intermittent maintenance therapy of daratumumab combined with low dose lenalidomide after transplantation, and the current remission period after transplantation reached 4 months.Conclusions:Daratumumab combined with chemotherapy bridging to allo-HSCT followed by daratumumab and lenalidomide may improve the prognosis of primary PCL and prolong survival time.

At present, the treatment methods of lymphoma mainly include the combined chemotherapy, hematopoietic stem cell transplantation, immunotherapy and new targeted therapies, but the treatment-related drug resistance, recurrence, extranodal and central nervous system infiltration, and leukemia transformation are still intractable problems that need to be solved in clinical practice. Studies have shown that cytokines are expressed to varying degrees in patients with lymphoma, which are significantly related to the progression of lymphoma, poor prognosis, chemotherapy response, and drug resistance. It has been confirmed that interleukin 6 (IL-6) and IL-10 are highly expressed in all types of lymphoma, and IL-10 is highly expressed in the cerebrospinal fluid of central nervous system lymphoma, all of which indicate a poor prognosis. This article reviews the role of cytokines in the development, treatment and prognosis of lymphoma.